Stay updated with breaking news from Steven Nathan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lixudebart (ALE.F02) is a first-in-class monoclonal antibody in clinical development for multi-organ fibrosis Alentis Therapeutics ("Alentis"), the clinical-stage biotechnology company developing
The Media Online’s weekly round up of people, account and business moves in media. All the media business moves you need to know.
Sens, an Irish market research firm blending behavioural science with BehaviourTech and AI, appoints Mike Abel, a global advertising leader, as non-executive chairman...
Up to 60,000 patients in the United States may have PPF, with only one approved therapy available ...
BASEL, Switzerland--(BUSINESS WIRE)--#CLDN1--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong a...